Skip to main content

Table 1 Vaccination-related input variables

From: Cost-effectiveness of human papillomavirus vaccination in Germany

Parameter Value Source
Vaccine efficacy HPV 16/18 in females 98% [81, 82]
HPV 6/11 in females (quadrivalent vaccine only) 100% [83]
HPV 16/18 in males 90.4% [84]
HPV 6/11 in males (quadrivalent vaccine only) 90.4% [84]
Cross-protection provided by the quadrivalent vaccine (considered in sensitivity analysis only) HPV 31/33/35/39/45/51/52/56/58/59 32.5% [85, 86]
Cross-protection provided by the bivalent vaccine (considered in sensitivity analysis only) HPV 31/33/35/39/45/51/52/56/58/59 68.4% [86]
Duration of full protection 10 years Assumption
Waning (after the duration of full protection) 0.1 per year Assumption
Vaccination coverage 50% Assumption
Age at vaccination 12 years Assumption
Booster vaccination No booster vaccination in the base case analysis Assumption
  1. HPV human papillomavirus